Immunologic, Virologic, Inflammatory, Coagulation, Metabolic, and Pentoxifylline Concentration Levels during the Trial.

Notes: Data presented as means (standard deviations) or as No. (%). All 13 placebo subjects had samples available at all study visits. Of the 13 pentoxifylline subjects, 11 and 10 had samples available at weeks 4 and 8, respectively. hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; TIMP-1, tissue inhibitor of metalloproteinase-1; sVCAM-1, soluble vascular cell adhesion molecule-1; sTNFRI and sTNFRII, soluble tumor necrosis factor-α receptors I and II; MCP-1, monocyte chemoattractant protein-1; IP-10, interferon-γ-induced protein-10; PAI-1 Ag, plasminogen activating inhibitor antigen-1; HOMA-IR, homeostatic model assessment-insulin resistance.1For comparisons between placebo and pentoxifylline groups.

备注：数据以均值（标准差）或例数（百分比）形式呈现。所有13名安慰剂组受试者在全部研究访视节点均留存可用样本。13名己酮可可碱组受试者中，分别有11名、10名在第4周、第8周留存可用样本。hsCRP（high sensitivity C-reactive protein，高敏C反应蛋白）；IL-6（interleukin-6，白细胞介素-6）；HDL-C（high density lipoprotein-cholesterol，高密度脂蛋白胆固醇）；LDL-C（low density lipoprotein-cholesterol，低密度脂蛋白胆固醇）；TIMP-1（tissue inhibitor of metalloproteinase-1，金属蛋白酶组织抑制剂-1）；sVCAM-1（soluble vascular cell adhesion molecule-1，可溶性血管细胞黏附分子-1）；sTNFRI与sTNFRII（soluble tumor necrosis factor-α receptors I and II，可溶性肿瘤坏死因子α受体I和II）；MCP-1（monocyte chemoattractant protein-1，单核细胞趋化蛋白-1）；IP-10（interferon-γ-induced protein-10，干扰素γ诱导蛋白-10）；PAI-1 Ag（plasminogen activating inhibitor antigen-1，纤溶酶原激活物抑制剂-1抗原）；HOMA-IR（homeostatic model assessment-insulin resistance，稳态模型胰岛素抵抗指数）。1 用于安慰剂组与己酮可可碱组的组间比较。